Try our Advanced Search for more refined results

Expert Analysis

Biotech Cos. Face Pressure To Disclose

Law360, New York (May 9, 2016, 3:50 PM EDT) -- When reacting to regulatory and clinical developments, management of a publicly-traded, clinical-stage biotechnology company, frequently may face a tension between a “duty to disclose” and the “pressure to disclose.” The “duty to disclose” material information is defined by legal principles. In contrast, the “pressure to disclose” is fueled by business and market realities. While every situation will be different, when deciding when and what to disclose, there are several practical steps that can be taken by management to facilitate and support that decision.

A biotechnology company with a product candidate in clinical trials faces many challenges. In addition to day-to-day operational...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Read the full article

Already a subscriber? Click here to login

Related Sections

Law Firms

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!